Clinical Trials at Saint Luke's Hospital of Kansas City
As of June 2026, 35 paid clinical trials are recruiting at Saint Luke's Hospital of Kansas City, located at 4321 WASHINGTON ST, SUITE 4000, KANSAS CITY, MO 64111-5961, phone (816) 932-2565 in Kansas City, Missouri. Active studies at this site cover conditions such as Heart Failure, Breast Cancer and Malignant Solid Neoplasm. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
35 clinical trials at Saint Luke's Hospital of Kansas City
·Clear filters·↓ Download CSVCCM OPEN HF Registry
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
RELIVE (Randomized Evaluation of Less Invasive Ventricular Enhancement) Trial
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
The Vanguard Study: Testing a New Way to Screen for Cancer
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
The Heart Outcomes in Pregnancy Expectations for Mom and Baby Study
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation
The PEERLESS II Study
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
The Percutaneous Transmural Arterial Bypass -1 Study (Post Approval Registry)
CTSN Embolic Protection Trial
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
The CONFORM Pivotal Trial
Quantification of Debris Captured Using TCEP During VIV TAVR With BVF
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
Effect of a Quality Improvement Initiative to Address Social Determinants of Health on Rehospitalization Rates in Patients With Heart Failure
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
About research studies in Kansas City
Kansas City has approximately 488 recruiting research studies across a wide range of therapeutic areas. Missouri hosts Washington University School of Medicine in St. Louis and University of Kansas Medical Center's Missouri partners, known for oncology, genomics, and rare-disease research.
Common conditions studied in Kansas City
- Heart Failure (18 active studies). Heart failure trials explore SGLT-2 inhibitors, novel myosin modulators, and device-based therapies for both reduced and preserved ejection fraction.
- Breast Cancer (13 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Malignant Solid Neoplasm (8 active studies). Recruiting Malignant Solid Neoplasm studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Atrial Fibrillation (7 active studies). Atrial fibrillation studies investigate next-generation anticoagulants, ablation technologies, and left atrial appendage closure devices.
- Neuroblastoma (7 active studies). Recruiting Neuroblastoma studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Acute Myeloid Leukemia (6 active studies). Leukemia trials evaluate targeted inhibitors, CAR-T cell therapies, and novel combinations for acute and chronic forms of the disease.
Leading research sponsors in Kansas City
- National Cancer Institute (NCI)
- AstraZeneca
- Children's Mercy Hospital Kansas City
- Children's Oncology Group
- Merck Sharp & Dohme LLC
Local regulations and guidelines
Clinical trials in Missouri are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. Missouri research additionally follows state public health department oversight and any applicable state privacy statutes.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in Kansas City. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in Kansas City
Hipa.ai aggregates every recruiting study in Kansas City from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in Kansas City?
There are approximately 488 recruiting clinical trials in Kansas City, Missouri listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Kansas City pay participants?
Most recruiting trials in Kansas City compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Kansas City?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Kansas City?
The most common conditions under active study in Kansas City include Heart Failure (18), Breast Cancer (13), Malignant Solid Neoplasm (8), Atrial Fibrillation (7), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Kansas City?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Kansas City on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Kansas City?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Kansas City?
Recruiting research sites in Kansas City include University of Kansas Cancer Center - North, Children's Mercy Hospital, Children's Mercy Hospitals and Clinics, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Kansas City right now?
The largest active categories in Kansas City are Cancer & tumors (157), Cardiovascular (60), Diabetes & metabolic (23). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Saint Luke's Hospital of Kansas City?
Saint Luke's Hospital of Kansas City is located at 4321 WASHINGTON ST, SUITE 4000, KANSAS CITY, MO 64111-5961. Use the Google Maps link in the intro above to get directions.
How do I contact Saint Luke's Hospital of Kansas City?
You can reach Saint Luke's Hospital of Kansas City by phone at (816) 932-2565. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.